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We are pleased to present our annual report from
the Children’s Mercy Cancer Program. The focus
this year is on germ cell tumors, a rare cancer type
representing about 3 percent of pediatric cancers.
This report illustrates our multidisciplinary
approach to pediatric cancer care. With numerous
other specialists like our surgeons, radiologists
and pathologists who join forces with pediatric
oncologists, our multi-specialty interdisciplinary
model of care makes the diagnosis and treatment of
children with cancer as seamless as possible.
By introducing you to our program, some of our
staff, and some of our patients, we believe that
you will understand why we are so proud of our
accomplishments.
Visit our website, childrensmercy.org, to learn even
more about our hospital and programs.

Maxine L. Hetherington, MD				
Editor
Principal Investigator, Children’s Oncology Group
Children’s Mercy Kansas City
Associate Professor of Pediatrics
University of Missouri-Kansas City School of Medicine
					

Alan S. Gamis, MD, MPH
Associate Division Director, Section of Oncology
Children’s Mercy Kansas City
Professor of Pediatrics
University of Missouri-Kansas City School of Medicine
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Cancer Registry
Review 2014
The Cancer Registry at Children’s Mercy Kansas
City is an important part of our care. The registry is
a database of confidential information concerning
all malignancies, benign brain tumors and other
specified conditions. The database is operated
under the guidance of the Cancer Care Committee,
with accreditation approval maintained by the
American College of Surgeons Commission on
Cancer. All data about diagnosis, treatment,
recurrence and survival must be collected in
standardized detail. Reporting is required by state
and federal law, as a means of comprehensive
cancer prevention and control programs.
Follow-up of cancer patients is an important part
of the registry activities. Knowing outcomes helps
the medical staff evaluate the best treatment and
the long-term effects of treatment. Follow-up letters
are sent out on a regular basis. Parents and older
patients also may contact the registry by secure
email at cancerregistry@cmh.edu to discuss followup. All of the registry operations are conducted
according to the Health Insurance Portability and
Accountability (HIPAA) privacy regulations.
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During 2014, the Cancer Registry added 195
patients. Of these patients, there were 167 patients
who were diagnosed with malignancies and
benign central nervous system tumors. There
were 28 patients added to the registry with benign
reportable conditions. These conditions are collected
at the request of the Cancer Care Committee for
surveillance purposes and are not required to
be reported outside our facility. The Frequency of
Diagnosis chart shows a breakdown of disease
types.
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Diagnosis
Central Nervous System
Astrocytoma
Glioma
Medulloblastoma
Ependymoma
Atypical Malignant Rhabdoid
Tumor (ATRT)
Glioblastoma
Choroid Plexus Carcinoma
Primitive Neuroectodermal
Tumor (PNET)
High Grade Tumor with
Differentiation
Pleomorphic Sarcoma,
Undifferentiated
Benign Borderline CNS
Leukemia
ALL
AML
Lymphoma
Non-Hodgkin
Hodgkin
Kidney
Wilms
Malignant Rhaboid Tumor
Neuroblastoma
LCH
Germ Cell
Bone Tumors
Rhabomyosarcoma
Non-Rhabdo Soft Tissue
Other Malignant
Hepatoblastoma
Retinoblastoma
Thyroid Carcinoma
Hepatocellular Carcinoma
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Teratoma, Benign
Desmoid Tumor
TMD- Transient
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Germ Cell
Tumors
Germ cell tumors (GCTs) are challenging. They
affect the entire spectrum of pediatric patients,
from newborn infants to young adults. About 900
children and adolescents are diagnosed with
GCTs in the U.S. each year, about 4 percent of all
childhood cancers. GCTs are the most common solid
tumor diagnosed in young adults.
Germ cell tumors are histologically diverse, ranging
from benign masses to life-threatening malignant
tumors, capable of spread from the primary
tumor to other parts of the body. Although the
majority of GCTs occur in the ovaries and testicles,
they can occur throughout the rest of the body in
extragonadal sites.
Presenting symptoms depend upon the tumor’s
location. A testicular GCT begins as a painless mass
in the scrotum. Ovarian and abdominal tumors
can present with abdominal pain, constipation
or a palpable abdominal mass. Mediastinal
tumors are in the area between the breastbone
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Type of Non-CNS Germ Cell Tumors
at Children’s Mercy by Histology

less than 10 percent chance of recurrence. When
teratomas have been completely resected, they are
evaluated to determine if any abnormal, immature,
malignant tissue is mixed in with the normal mature
tissue. If AFP or B-HCG levels are elevated prior to
surgery, it is presumed that there is some malignant
component to the tumor. Following surgery, if tumor
markers normalize, additional therapy may not
be necessary. If there is a malignant tumor of the
ovary or testicle that is removed, without evidence
of tumor spread by staging studies, there is up to
a 50 percent chance of tumor recurrence. If active
surveillance rapidly diagnoses recurrent tumor,
more than 90 percent of children with recurrent
tumor can be cured with chemotherapy. If there
is known macroscopic residual malignant tumor,
chemotherapy is administered. Radiation therapy
is used most commonly in children who have GCTs
affecting the brain or spinal cord.
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and spinal column, and can cause chest pain or
shortness of breath or wheezing from compression
of the windpipe. Sacrococcygeal tumors
are often found in infants. They arise from
the tissue above the tailbone, and can
extend either externally and can be seen
on prenatal ultrasound or at birth, or can
extend internally, causing constipation,
urinary retention or pain. GCTs affecting the
brain can present with visual disturbances,
headache or vomiting.
N = 39
Some of these tumors are easily palpable
on physical examination. Imaging studies
can be done to evaluate the primary tumor
and to determine if the tumor has spread
to other parts of the body through either
the lymphatic pathways into lymph nodes,
or the bloodstream to distant parts of the
body such as the lungs, liver, bones or
brain. Malignant tumors can produce specific
chemical markers such as alpha fetoprotein (AFP)
and beta human chorionic gonadotropin (B-HCG)
that can be found in elevated levels in the blood.

Children’s Oncology Group (COG) Staging of
Non-CNS Germ Cell Tumors at Children’s Mercy
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Benign teratomas contain all mature, normal kinds
of tissue, including bone, cartilage, hair, fat and
teeth. They can be cured with surgical excision, with
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The most common treatment regimen in adults is a
combination of bleomycin, etoposide and cisplatin,
termed BEP. It has been used for more than 40
years, and transformed metastatic testicular cancer
in adults from virtually incurable to about 90 percent
curable. The treatment regimen has been modified
in children to reduce the use of bleomycin, and to
shorten the treatment in the majority of patients,
7

called PEB. Although the BEP regimen has been very
successful in adults, there are many known side
effects. Secondary malignancies occur in as many
as 47 percent of long-term survivors. Radiation
therapy contributes to an increased incidence of
secondary malignancy. The use of etoposide is
associated with secondary leukemia. Bleomycin
can result in pulmonary insufficiency. Cisplatin
can result in reduced kidney function, renal saltwasting, hearing loss and tinnitus. Infertility can
be an issue because of surgery, chemotherapy or
radiation therapy. There is an increased incidence
of cardiovascular disease in the adult survivors of
testicular cancer.
The causes of childhood GCTs are not known.
However, we do recognize that males with
undescended testicles have an increased risk to
develop testicular GCTs. Some genetic syndromes
characterized by extra or missing sex chromosomes
can be associated with an increased incidence
of germ cell tumors. Men who use musclebuilding supplements that contain creatine or
androstenedione may have up to 65 percent
increased risk of developing testicular cancer.

Sex of Patients with Non-CNS Germ Cell Tumors
at Children’s Mercy

N = 39
Males = 21
Females = 18
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Male
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Since we don’t know many of the causes for
childhood GCTs, prevention is impossible. It is
recommended that boys with undescended
testicles undergo orchiopexy to reduce the risk of
the development of testicular tumors later in life.
Teaching young men that testicular cancer is the
most common cancer of adolescents and young
men may allow for more rapid recognition of
tumors, prior to systemic spread.

“

Germ cell tumors
are the most
common solid
tumor diagnosed
in young adults.

“

Anatomic Site of Non-CNS Germ Cell Tumors
at Children’s Mercy

Percent Survival

Clinical trials are used routinely in pediatric oncology
to improve cure rates and reduce longterm side effects of therapy. However,
Overall Five Year Survival of Non-CNS Germ Cell Patients
at Children’s Mercy - 2005-2014
participation in clinical trials is far less
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common in adults, especially in newly
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diagnosed GCTs, in which the cure rate
is so good with standard therapy. Many
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different practitioners care for young adults
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with GCTs, including pediatric oncologists,
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medical oncologists, gynecologic oncologists
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and urologic oncologists. It’s been hard
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to get this diverse group of physicians to
30
collaborate, but collaboration is on the
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horizon. Clinical trials for standard risk,
high risk and recurrent germ cell tumors
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being discussed.
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Harper Atkinson
After a seemingly normal pregnancy, Mandi and
Daniel Atkinson didn’t expect anything unusual
following the birth of their first daughter, Harper.
However, something abnormal caught the eye of
the family’s OB-GYN immediately following her birth.
“The doctor noticed very quickly that there was
a lump on her lower back stemming from her
tailbone,” said Mandi. “We were sent to Children’s
Mercy where they did an MRI.”
From the results, doctors concluded Harper had a
tumor—a sacral teratoma.
“We were told that most teratoma tumors are
benign, so we weren’t super worried about it being
malignant, and we don’t have any history of
pediatric cancer in our family, so we just hoped
for the best,” explained Mandi.
But, pathology results concluded the tumor
was malignant.
“We were shocked,” said Mandi.
“Harper was our first child and neither
Daniel nor I have any medical
problems. We just weren’t prepared
for it. It was a whirlwind of events
as soon as we got the diagnosis.”
Surgeons at Children’s Mercy
successfully removed the tumor
from Harper’s tailbone and
she was discharged a week
later.
Once the Atkinsons finally
got their newborn home,
Harper’s incision split
open, forcing them back
to the emergency room.
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“We were home less than 24 hours before returning
to the hospital for another week, so we had a little
bit of a rocky road to start with,” said Mandi.
When Harper was admitted to the hospital for a
second time, the Atkinsons were introduced to
Maxine Hetherington, MD, Pediatric Hematologist/
Oncologist.

“I can’t say enough about the NICU nurses Harper
had during our stay. They were wonderful,” Mandi
said. “We have the same nursing and tech staff
every time we come back, which has been great.
I don’t want to say that we look forward to going,
because we don’t, but it’s not nearly as painful
when you know you have great people taking care
of you.”

“We recommended holding off on chemotherapy,”
explained Dr. Hetherington. “Harper’s alphafetoprotein (AFP) level was extremely high, which
is common right after birth, but can also indicate a
malignant tumor. We went with our gut feeling and
observed Harper after surgery in hopes that the
tumor had been completely removed.”
“In the beginning, labs were showing that her AFP
level was going down really well, but stopped
going down as rapidly as we would’ve hoped
around her two-month mark,” said Mandi.
At that time, it was up to Dr. Hetherington to
decide what the best plan of action was: continue
observation, or move on to chemotherapy?
Harper’s AFP level remained exceedingly high,
sparking concern that a piece of the tumor may
have been missed in surgery. Because of this,
Dr. Hetherington consulted with other pediatric
oncologists and experts in the treatment of
malignant germ cell tumors. They recommended
Dr. Hetherington and her team hold off on
chemotherapy, advising them to remain patient.
Instead, they scheduled monthly check-ups to
monitor Harper’s AFP level.
“Those were some trying months of waiting it out
and praying that her AFP level went down instead
of up,” said Mandi. “But we’ve got a lot of trust in
Dr. Max and her team—they’ve never led us astray
and we had wonderful care the whole time we were
there.
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Harper is now nearly 2 ½ and hasn’t looked back
since surgery. She continues to have regular checkups and monitoring of her AFP level.
“We’ve followed up with the oncology department
every month faithfully to check labs. We hope to
decrease the frequency of check-ups because that
would mean her lab results are more normal than
before,” Mandi said. “No one would ever know
anything was ever wrong with Harper at this point—
she’s hit all of her milestones to date.”
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General Surgery
Pediatric germ cell tumors are a heterogeneous
group of neoplasms generally divided into gonadal
and extragonadal types. The most common type
of germ cell tumor is the teratoma. Teratomas that
occur in infancy are usually extragonadal, while
those occurring in older children and adolescents
most often are found in the testis or ovaries. The
current treatment of pediatric germ cell tumors
consists of surgical resection and selective
chemotherapy.
Pediatric general surgeons are experienced in the
management of both gonadal and extragonadal
tumors. The gonadal germ cell tumors are also
often managed by our pediatric urology and
pediatric gynecology colleagues. However, the
surgical management of extragonadal germ cell
tumors is primarily provided by pediatric general
surgeons.
The surgical treatment is determined by the location
and extent of the tumor. The recommendations for
specific sites of extragonadal germ cell tumors are:

Sohail Shah, MD
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Mediastinal teratoma: This is the second most
common site for extragonadal germ cell tumors.
These tumors may be diagnosed from the fetal
period to adolescence. The potential for airway
complications makes appropriate management
during general anesthesia of paramount
importance. These tumors are similarly preferentially
treated with complete surgical excision, with biopsy
and chemotherapy reserved for tumors that are
deemed unresectable.
Abdominal and Retroperitoneal teratoma:
The most common abdominal teratomas are
the gonadal teratomas; however, extragonadal
teratomas do occur in the abdomen and
retroperitoneum. These tumors are treated similar
to other teratomas and may be large or noted to
encase major vessels. In these cases, the tumors
are biopsied and initially treated with chemotherapy.
Pediatric germ cell tumors are an extremely varied
group of neoplasms that necessitate a focused
preoperative evaluation and multidisciplinary
approach to treatment.

“

Teratomas that
occur in infancy
are usually
extragonadal,
while those
occurring in
older children
and adolescents
most often are
found in the
testis or ovaries.

“

Sacrococcygeal teratoma: This is the most
common tumor in the newborn, and is the most
common germ cell tumor overall. It is often
diagnosed by routine prenatal ultrasound. Repeat
imaging is often used to follow in-utero progression
and further determine the size, location, complexity,
and extension. Depending on tumor presentation,
some of these are not diagnosed until later in
childhood, and these are more often malignant.
Complete surgical excision remains the initial
treatment of choice. Tumors that are deemed to be
unresectable upon initial presentation are biopsied
and followed with chemotherapy. An incompletely
excised lesion does increase the chance of
malignancy.
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Pathology
Germ cell tumors are neoplasms that arise
from the germ cells either located in the
gonads or in extra-gonadal locations, such as
mediastinum, cranial cavity or the retroperitoneum.
Morphologically, these tumors are classified into
mature teratoma, immature teratoma, seminoma/
dysgerminoma, embryonal carcinoma, yolk sac
(or endodermal sinus) tumor, choriocarcinoma and
gonadoblastoma. Patients may harbor either a
pure, histologically single germ cell tumor or may
develop a mixed germ cell tumor, wherein more
than one neoplastic cell type is present in the tumor.
To diagnose germ cell tumors, pathologists employ
a battery of immunohistochemical stains that
identify the neoplastic cells. Some of the typical
antigens expressed by the germ cell neoplasms
are: AFP in yolk sac tumor, PLAP in seminoma,
HCG in choriocarcinoma and CD30 in embryonal
carcinoma. However, these markers do not have
a very high sensitivity or specificity to be used
in isolation. Thus, multiple antibodies are used
in a panel to provide an unequivocal diagnosis.
Teratomas are an exception for the need to
use immunohistochemical stains because this
neoplasm has a distinctive appearance on routine
hematoxylin-eosin stains.
Serum tumor markers are a valuable tool to
aid in the diagnosis and follow-up of patients.
Serum levels of alfa-fetoprotein, human
choriogonadotrophin, placental-like alkaline
phosphatase when significantly elevated prior to the
treatment of the neoplasm, can be used to monitor
tumor burden or recurrence. Some syndromes such
as Trisomy 21 and Klinefelter, undescended testes
and streak gonads increase the risk of developing
germ cell tumors.
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Radiology
The Diagnostic Radiology department at Children’s
Mercy is an important part of the care of a child with
a germ cell tumor. A variety of imaging studies may
be utilized for initial diagnosis, pre-surgical planning
and routine surveillance to monitor the tumor’s
response to therapy.
Though a germ cell tumor may be initially
diagnosed with an X-ray or an ultrasound,
advanced cross-sectional imaging with computed
tomography (CT) or magnetic resonance imaging
(MRI) is commonly used to define the tumor and
its relationship to adjacent body structures. The
addition of new CT scanners throughout the
Diagnostic Radiology department allow for faster
scan times and decreased radiation dose without
sacrificing image quality. Children’s Mercy has four
MRI scanners, providing state-of-the-art imaging at
our Adele Hall, South and East campuses.
As a CT or MRI examination can be a frightening
experience, some children may require the care of
our sedation nurses or pediatric anesthesiologists.
However, creation of a comfortable environment
and distraction techniques by our team of imaging
experts and Child Life specialists may remove the
need for sedation.
15

Cytogenetics
Cytogenetics is a laboratory specialty that studies
tissues to determine genetic changes that occur in
the cells of tumors. Since all cancers have genetic
changes and these changes are specific to each
tumor, it is important to investigate each child’s
tumor. Certain genetic changes can help define the
tumor type and other genetic changes may help
determine the best therapy for treatment.
The cytogenetics laboratory uses several methods
to investigate. One method grows the tumor cells
and then captures the cells when they divide so
the chromosomes can be seen. Chromosomes
are where the genes reside. Another method uses
fluorescent probes to look at specific genes to
determine if something has happened to the gene.
Several methods use the genetic material, DNA,
after it is isolated from the tumor cells. DNA can be
used for microarray analysis and various molecular
tests. Microarray analysis investigates tumor DNA by
looking for changes throughout the genome.
The molecular genetics laboratory uses methods
to look deeply into the genes with some methods
looking at specific genes and other methods

Linda Cooley, MD
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sequencing or “reading” all the genes in the
genome. The goal of the studies is to detect
mutations or changes specific for the tumor being
studied.

GCTs in adults and post-pubertal children are
characterized by extra copies of the chromosome 12
short arm (12p), or part of 12p. Other chromosome
anomalies occur in this age group, which are
different from those found in the GCTs of infants and
prepubertal children. Gain of 12p is rarely reported
in prepubertal children and infants. Microarray
analysis has shown that 12p is affected differently
in adult GCTs and GCTs of very young children. GCTs
are rare in children between ages 5 and 9 years,
thus there is little known about the genetics of
tumors from this age range.

Results obtained from these studies provide the
oncology team with a genetic picture specific to
each child’s tumor. This information is used along
with all other laboratory and clinical information in
planning for the optimal care of each child.
Specifically, germ cell tumors are a group of
rare tumors that can arise in the gonads and at
other places in the body. The clinical course and
outcome of the various GCTs differ. Tumors can
be found from newborn to old age. Testicular
GCTs are the most common tumor in males
ages 10 to 40.Cryptorchidism is associated with
approximately 10 percent of testicular GCTs.
Testicular GCTs in infants are rare neoplasms
occurring in boys 0–4 years. Ovarian GCTs may
occur in patients with gonadal dysgenesis. Rarely,
GCTs occur extragonadally in the brain, mediastinal
or sacrococcygeal regions. Pediatric mediastinal
GCTs have the same histologies as gonadal GCTs,
but have a worse prognosis. The mediastinum is
a common site in young males and these tumors
are associated with Klinefelter syndrome in
approximately 20 percent of cases. Sacrococcygeal
GCTs, the most common extragonadal GCT in
children, present prenatally to approximately 4
years.
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Gynecology
Germ cell tumors of the ovary are relatively common
solid neoplasms of children and adolescents that
form probably due to abnormal differentiation of
fetal germ cells. The risk of developing a germ cell
tumor of the ovary increases with age until about
the age of 15- 19. Most germ cell tumors of the ovary
are benign cystic teratomas with only 1-3 percent
having malignant features. Seventy percent of all
malignant ovarian tumors are germ cell in origin.
Benign teratomas can form in several areas of
the body, with the ovary being the second most
common site. These tumors have components
deriving from all embryonic layers and developing
tissues that are otherwise not seen in the ovary.
They may accumulate fluid and contain structures
such as hair, teeth and sebaceous material, and
on occasion grow to a very large size. This can be
associated with replacement of normal ovarian

Julie Strickland, MD
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Often, these tumors are first seen incidentally upon
imaging with ultrasound, X-ray or CT scanning
with their characteristic findings of calcification
and fat present within the cystic ovary. Surgical
management of ovarian teratomas is commonly
done through minimally invasive surgery with
conservation of the ovary involved. The prognosis
with this technique is excellent with a less than 10
percent risk of recurrence.
Occasionally, teratomas may have malignant
features associated with immature elements.
Despite their malignant potential, they have a
good prognosis with adequate surgery and close
postoperative surveillance. Resection of these
tumors, along with careful assessment at the time of
surgery and with imaging, is essential as recurrence
can be as high as 33 percent. Recurrence risk
is related to both the size and completeness of
resection. Conservative, fertility sparing surgical
treatment of malignant teratomas and other germ
cell neoplasms is strongly encouraged. Often, the
tumor may secrete markers such as AFP and hCG
which allow monitoring for relapse.
Other types of malignant germ cell tumors are
rare and can require both surgical removal and
chemotherapy. Before current developments
in chemotherapy, the 10-year survival rate for
malignant germ cell tumors ranged from 25
percent for embryonal carcinoma to 75 percent
for dysgerminoma. Today, overall survival rates
are greater than 90 percent with fertility sparing
conservative surgery and chemotherapy.
At Children’s Mercy, pediatric gynecologists and
surgeons work closely with oncologists and
diagnostic radiologists to treat germ cell tumors of
the ovary. Emphasis is placed on fertility.

“

Before current
developments in
chemotherapy, the
10-year survival rate
for malignant germ
cell tumors ranged
from 25 percent for
embryonal carcinoma
to 75 percent for
dysgerminoma.
Today, overall survival
rates are greater
than 90 percent
with fertility sparing
conservative surgery
and chemotherapy.

“

tissue, as well as pain from ovarian torsion (twisting)
and cyst rupture.
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Urology
Malignant testis tumors are rare in children. The
risk for malignant tumors increases after boys go
through puberty. In boys, most tumors are benign. In
adults, the vast majority are malignant.
The approach to a testicular mass in a boy
before puberty is often biased toward a testissparing approach. Unless specific lab markers for
malignancy are present, the tumor is removed from
the testis and if it proves to be a benign lesion, the
remaining testis is preserved. Benign tumors require
no further therapy after surgery.
In boys after puberty, these lesions are most
commonly malignant and the entire testicle is
removed. In this setting, work is undertaken to see if
the tumor has spread.
The mainstay of therapy for malignant tumors is
chemotherapy. Sometimes radiation is used. If the
tumor has spread to the abdominal lymph nodes
and does not disappear with this therapy, they may
require surgery.

John Gatti, MD
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At Children’s Mercy, we have a close relationship
with our adult urology colleagues at the University
of Kansas and maintain a role as teaching faculty
at both institutions. If an abdominal operation to
remove lymph nodes is required, these children are
often referred to KU.
Screening for Testis Tumors
As boys enter puberty, heralded by the growth
of underarm and pubic hair growth, they are at
increasing risk for testicular malignancy. These
most commonly tend to occur from the age of 15
to 40 years. The risk is higher in boys with a history
of having an undescended testis. Testis tumors
may also be more common with some genetic
syndromes or a significant family history.
Once puberty begins, we recommend that boys
begin performing testicular self-examination to
become familiar with the shape and consistency of
the testes and to identify any suspicious masses.
These tend to be hard, painless lumps in or on the
testis itself. If a mass is found, medical evaluation is
warranted.

“

The approach to
a testicular mass
in a boy before
puberty is often
biased toward
a testis-sparing
approach.

“

Overall cure rates for testicular cancer are greater
than 90 percent. The common tumors we consider
are very different in pre-pubertal boys compared to
post-pubertal boys, and boys progressing through
puberty at the time of diagnosis present a unique
challenge because the tumor may exhibit the
behavior of either group.
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Genomics and
Biorepository
The Children’s Mercy Cancer Genomics Program
is the work of the Children’s Mercy Cancer Center
and the Center for Pediatric Genomic Medicine.
The program makes next-generation sequencing
research available to all oncology patients. Any
child, adolescent, or young adult who is treated for
a germ cell tumor at Children’s Mercy may enroll in
a research protocol for genomic sequencing. Once
enrolled, DNA from the patient’s healthy blood cells
and DNA from the patient’s tumor cells are analyzed
and compared. The result is a detailed report of the
tumor’s biology, which can help researchers better
understand the causes of germ cell tumors. In some
cases, genomic sequencing may help clinicians
choose treatments that are targeted to each
patient’s tumor.
Beginning in 2016, part of the support for the Cancer
Genomics Program and other research programs,
will be the Cancer Center Biorepository. Patients
with germ cell tumors may opt to donate blood,
leftover tumor samples, DNA and clinical data to
the Biorepository. The donated material and clinical
data are stored in a protected database and are
available to research scientists with approved
protocols to study cancer and related diseases.
By participating in the Biorepository, patients with
germ cell tumors provide a critical resource needed
to make progress toward targeted treatments and
even better cure rates.

Erin Guest, MD
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Advanced Practice
Nurses
Advanced Practice Nurses are a part of the care
team for patients with germ cell tumors. APNs are
master’s or doctoral-prepared nurses who partner
with the patient’s physician to provide individualized
care. This approach allows for consistent providers
for the patient and family. APNs provide case
management services for patients’ total therapy
needs. Patients with germ cell tumors often require
specific labs, chemotherapy, radiology imaging,
inpatient and outpatient treatments, and home
care. All of these needs are well coordinated by
the APN. The APN provides education throughout
the process. The APN reviews the therapy and
how it is affecting the patient, performs physical
examinations, orders laboratory tests and scans,
and prescribes medications. The APN is the point
person for phone contact when families are home.
Children’s Mercy also has APNs that manage the
inpatient chemotherapy service. They see the
patients in the morning, do physical exams, adjust
medications and round with a physician each day.
They are able to provide continuity of care for these
patients who are frequently hospitalized.
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FaCT Team
Outside of medically directed care, patients and
families have many other needs addressed by our
Family Care Team (FaCT). Regular FaCT rounds and
collaboration ensure that physical, developmental,
emotional, educational and spiritual needs are met
for our patients and families. The Family Care Team
is available to assist from point of diagnosis through
the completion of treatment and beyond.
Child Life Specialists promote a positive
environment for patients and families. This is
accomplished by providing materials and guidance
for developmentally appropriate play, preparing
children for medical experiences, advocating for
patient and family rights, and promoting a nonthreatening environment. Our team tries to reduce
stress and worry. We help children deal with their
feelings, thoughts and questions. We provide
services to help children continue to learn and grow
while in the hospital.
Clinical Social Workers are licensed professionals
working as part of the primary team. The social
worker understands that any change in the child’s

Liesel Stephens, MT-BC,
Music Therapy

Stephanie Easley, CCLS,
Child Life
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health can alter a family’s life in many ways and
they are trained to provide a thorough assessment
and address the needs of the patients and
families. Social workers can help with adjustment
to illness, crisis intervention, development of
coping skills, family concerns, advanced directives,
end of life, bereavement, school concerns, legal
issues, transition to adult care and community/
resource referrals to assist with financial concerns,
transportation and lodging needs, support and
mental health.
The Parent to Parent Program offers support and
comfort to all families through the Parent Rooms,
Peer Match Program, and bereavement follow-up.
Among the services offered are: trained parent
mentors available to share, listen, and support
current parents; two stocked parent rooms that
offer weekly dinners, breakfasts, therapeutic and
educational activities and a safe place to unwind
while a child is an inpatient; and “care bags” for
new families upon admission to help ease some
burden of a hospital stay. The Parent to Parent
program also offers an extensive bereavement
follow-up program (including social media) that
supports families after a child’s death.
The Hematology/Oncology Division has two
psychologists to assist patients and families with
coping with the diagnosis and treatment of germ
cell tumors and other cancers. They are available
to meet with patients and their families both while
hospitalized and when an outpatient. In addition
to therapy services, the psychologists are also
able to complete neurocognitive evaluations to
assess any impact of medical treatment on brain
functioning and to assist with school re-integration
and planning.
The Chaplain working with Hematology/Oncology/
BMT is available to meet and provide spiritual
and emotional support for patients and families
during the course of the child’s illness, as end-oflife discussions are necessary, at the time of death
and beyond. The chaplain can assist in contacting a

Amanda Trout, LMSW, LCSW
Social Work

family’s own clergy if requested, or locating a local
clergy of the patient/family’s denomination or faith
for families who are not from the area. The chaplain
also provides education on spiritual resources and
support available within the hospital including the
chapel, worship opportunities and special events.
Additionally, the chaplain provides support to
members of the staff.
Music Therapy services are offered to patients and
families at bedside to address the specific needs
of each individual patient. Music interventions
are designed after an assessment of need, and
generally involve the use of both live vocal and
instrumental music. Goals may include (but are not
limited to) the reduction of pain or anxiety; increased
self-expression, movement, or relaxation; and the
support of developmental skills.
An on-site school teacher works with patients
primarily on the inpatient floor with some availability
in clinic as needed to assist with the challenge of
keeping up with school work. Our school teacher is
able to communicate directly with the child’s school
to get current assignments and also to advocate for
the patient’s needs once they return to the school
setting.

25

Survive & Thrive
The Survive & Thrive Program offers comprehensive
medical and emotional care to childhood cancer
survivors who are at least two years off treatment
and five years from the date of diagnosis. Survivors
are at risk for late effects from their cancer and
treatment. Late effects of treatment can be
physical or emotional and typically appear at ages
10-20. The development of late effects may be
influenced by the type of cancer, the treatment,
age at diagnosis and genetic predisposition. An
estimated 75 percent of childhood cancer survivors
will develop at least one late effect at some point
during their life. Late effects may be preventable or
modifiable, which is why yearly lifelong follow-up is
important for all survivors.
Examples of late effects that may occur in survivors
with a history of germ cell tumor include hearing
loss, lung dysfunction, and development of a
second cancer. In the Survive & Thrive Clinic,
survivors are monitored for development of late
effects based on the treatment they received and
according to the Children’s Oncology Group Longterm Follow-up Guidelines. The team ensures any
recommended testing is performed and monitors
those results. The Survive & Thrive team works
closely with health care providers in other specialties
to ensure each survivor’s unique health needs are
met.
A visit to the Survive & Thrive Clinic includes a
thorough physical exam, recommendations for
long-term follow-up care, education on late effects
and recommendations for maintaining a healthy
lifestyle. Included in the visit are nutritional and
psychosocial assessments. As survivors reach the
teenage years, preparation for transition to adult
providers is incorporated into each visit. The Survive
& Thrive team works with each survivor to help them
learn how to advocate for their health care needs
once they leave the pediatric setting.
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Fertility Preservation at
Children’s Mercy
With increased survival of pediatric cancer patients,
there comes more focus on quality of life post-treatment.
Cancer treatment may affect the survivor’s fertility. A fertility
preservation team has begun work to explore this unfortunate
side effect. The team consists of a social worker to help
address the financial concerns, nurse practitioners who have
all received specialized training in fertility preservation, and a
lead physician to answer medical questions.
The team is available to meet with patients and their
families at the time of diagnosis to review options
available for fertility preservation prior to treatment. The
team can help coordinate services and answer questions
about options. Sometimes, patients are not able to
preserve fertility prior to treatment due to the need to
immediately start therapy or age/maturity level of the
patient. If that is the case, the team can help discuss posttherapy options and the risk of treatment. A patient’s risk
of infertility depends on multiple factors, including type/
dose of chemotherapy, radiation location/dose and
certain types of surgery.
Options that are available for fertility
preservation in the Kansas City area
include sperm cryopreservation,
egg harvesting/cryopreservation or
embryo cryopreservation. After cancer
treatment, many of our survivors
will recover fertility, but for those
that do not, options include in vitro
fertilization with donor egg/sperm,
surrogacy, embryo adoption,
international or domestic adoption
or adoption through the foster
care system.
For more information regarding
this service please contact Joy
Fulbright, MD, at (816) 302-6808.

27

27

Canines Hunter
and Hope Join
Children’s Mercy
Staff
Children’s Mercy recently welcomed two golden
retrievers to the staff.
Hunter and Hope are on the job at the Adele Hall
Campus and Children’s Mercy Hospital Kansas
(respectively), delivering comfort, cheer and daybrightening tail wags to help patients on their road
to recovery. Hunter is stationed in the Hematology/
Oncology area, working with patients with cancer;
Hope works in the Comprehensive Epilepsy Center.
With Hunter’s and Hope’s presence, lives of
Children’s Mercy patients are being changed for the
better.
“We’ve had dogs here at Children’s Mercy for
years, primarily through ‘Pet Pals,’ a program
where volunteers bring their dogs to the hospital
on Thursday evenings for a group session,” said
Missy Stover, Child Life Volunteer and Therapeutic
Programs Manager and Manager of the Facility Dog
Program. “We also have dogs in our Rehabilitation
Unit on Wednesdays to help kids meet their therapy
goals. But we’ve always thought how wonderful it
would be if we could have a dog here every day. It’s
been a dream of mine.”
Now that dream is a reality.

Hunter
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Hunter with handler, Aimee Hoflander and Hope
with handler, Allison Bowring, from our Child Life
Facility Dog Program.

Both dogs were trained at Canine Assistants, an
Atlanta organization that provides service dogs to
individuals and facility dogs to pediatric hospitals
across the country.
“We got to go to the hospital (in Atlanta) and see
the dogs work their magic,” Missy said. “We really
feel like our kids will benefit. They are amazing
dogs.”
Therapy dogs are credited with helping meet
patients’ physical and emotional needs, taking
their minds off pain and problems, reducing
anxiety and promoting shorter recovery
times.
A 10-year-old Atlanta patient’s
testimony sums up what a
therapy dog can do: “He
turned my frown upside
down.”
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Hunter at play with a
young cancer patient.
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